Abstract

Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium

Author(s): Jones Marty

Issue: Jan/Feb 2000 - Compounding for Pain Management

Page(s): 6-15

Download in electronic PDF format for $75
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 1
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 2
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 3
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 4
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 5
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 6
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 7
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 8
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 9
  • Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium Page 10

Abstract

Recent reports of N-methyl-D-aspartate receptor antagonists, glutamate antagonists, alpha2-agonists, gamma-aminobutyric acid agonists, alpha1-antagonists, opioids and antioxidants in various combinations provide the contemporary rationale that is furnishing increased efficacy in the clinical management of chronic neuropathic pain, with fewer side effects. This article focuses on this new theory as an approach, from the perspective of a compounding pharmacist, to provide better control of chronic neuropathic pain in the new millennium. Implementation of this theory in daily practice within the triad of care will enhance the odds of positive outcomes in patients suffering from chronic neuropathic pain. The author focuses on pathophysiology, evidence, a new approach and clinical compounding success. He concludes that this is a huge market and that the efficacy is significant using the approach presented in this article.

Related Keywords

  • allodynia
  • amantadine
  • AMPA receptors
  • baclofen
  • carbamazepine
  • clonidine
  • compounding
  • DermiGel
  • dermis
  • dextromethorphan
  • diabetic peripheral neuropathy
  • epidermis
  • fibromyalgia
  • free radicals
  • GABA receptors
  • gapabentin
  • HbA1c
  • hyperalgesia
  • ketamine
  • memantine
  • neuropathic pain
  • nifedipine
  • NMDA receptors
  • opioids
  • opium
  • orphenadrine
  • pain
  • pain management
  • phenytoin
  • PLO
  • postherpetic neuralgia
  • prazosin
  • reflex sympathetic dystrophy
  • speed gel
  • tricyclic antidepressants
  • valproic acid
  • VanPen
  • dermatome

Related Categories

  • MENTAL HEALTH
  • PAIN MANAGEMENT

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2000
Pg. 6-15
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium
Author(s): Jones Marty
May/Jun 2010
Pg. 182-192
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Jan/Feb 2002
Pg. 4-6
Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance
Author(s): Jones Marty
Mar/Apr 2000
Pg. 91-93
Transdermal Gels in the Treatment of Diabetic Neuropathy
Author(s): Hodges Caroline J, Jones Thomas H, Willoughby David L
Jan/Feb 2003
Pg. 21-23
Profile of a Practice: Ward Drug Company Diabetic Shoppe and Prescription Compounding Center
Author(s): Vail Jane
May/Jun 2010
Pg. 200-203
Topical Medications for Orofacial Neuropathic Pain
Author(s): Bramwell Bethany L
May/Jun 2020
Pg. 182-186
Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1
Author(s): Riepl Mike
Mar/Apr 2024
Pg. 100-109
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
May/Jun 2007
Pg. 202-211
Levorphanol for the Treatment of Severe Chronic Pain
Author(s): McNulty Jack P
Jan/Feb 2022
Pg. 65-71
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Jul/Aug 2004
Pg. 265-267
Case Report: Wound Care of a Diabetic Foot Ulcer
Author(s): Wynn Tom
Mar/Apr 2024
Pg. 135
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Author(s): Allen Loyd V Jr
Mar/Apr 2006
Pg. 159-160
PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
Author(s): McNulty Jack P
May/Jun 2009
Pg. 182-190
Update on Managing Neuropathic Pain
Author(s): McNulty Jack P, Muller George
May/Jun 2016
Pg. 231
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Author(s): Allen Loyd V Jr
May/Jun 2010
Pg. 193-199
The Role of Sex Hormones on Fibromyalgia Pain Mediators
Author(s): Bramwell Bethany L
Sep/Oct 2005
Pg. 339-346
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Author(s): Mishkan Emilyn S
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Mar/Apr 2000
Pg. 84-87
The Clinical Pharmacist's Role in Compounding for the Diabetic Patient
Author(s): Harshbarger Robert, Harshbarger Diana